Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,507 result(s) found for: Blood Disease. Displaying page 89 of 526.
    «« First « Previous 85  86  87  88  89  90  91  92  93  Next» Last»»
    EudraCT Number: 2014-004900-31 Sponsor Protocol Number: A8241022 Start Date*: 2015-05-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021
    Medical condition: HUNTINGTON'S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    17.1 10010331 - Congenital, familial and genetic disorders 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002226-79 Sponsor Protocol Number: AUGEAS Start Date*: Information not available in EudraCT
    Sponsor Name:Region Skåne
    Full Title: A 30-day, randomized, evalUator-blind, controlled, multi-centre, parallel Group, phase III study to evaluate the Effect of a Low Maintenance Dose TicAgrelor Regimen versus Standard Dose Clopidogrel...
    Medical condition: Coronary Artery Disease (CAD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    20.0 10007541 - Cardiac disorders 10072685 Microvascular coronary artery disease PT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    21.1 10042613 - Surgical and medical procedures 10065608 Percutaneous coronary intervention PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000217-30 Sponsor Protocol Number: 3098012 Start Date*: 2015-06-16
    Sponsor Name:Orion Corporation
    Full Title: EFFICACY OF ORM-12741 ON AGITATION/AGGRESSION SYMPTOMS IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE STUDY OF 12 WEEKS
    Medical condition: The agitation/aggression symptoms in patients with Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) PL (Completed) BG (Completed) RO (Suspended by CA) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002986-39 Sponsor Protocol Number: DXM/AMT Start Date*: 2011-09-12
    Sponsor Name:Profil Institut für Stoffwechselforschung GmbH
    Full Title: A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Fourfold Cross-Over Study to Investigate the Glucose Lowering Effects of Dextromethorphan and Amantadine in Subjects with Type 2 Diabetes ...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021349-36 Sponsor Protocol Number: VRP100419 (CHDR1018) Start Date*: 2010-11-08
    Sponsor Name:Verona Pharma plc
    Full Title: Randomised, Double-Blind, Placebo-Controlled Evaluation of the Safety and Duration of Action of 2 Single Inhaled Doses, 0.036 mg/kg (12X) and 0.072 mg/kg (24X), of RPL554, a Dual PDE 3/4 Inhibitor,...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002645-11 Sponsor Protocol Number: SPP1C302 Start Date*: 2013-12-04
    Sponsor Name:SBI Pharmaceuticals Co., Ltd.
    Full Title: An Open-label, Randomized Study to Evaluate Safety, Tolerability and Pharmacokinetics of 5-ALA/SFC in Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia.
    Medical condition: Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10002034 Anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-004445-26 Sponsor Protocol Number: A65870 Start Date*: 2015-03-27
    Sponsor Name:World Health Organization
    Full Title: A phase III, randomized, double-blind, active, controlled, multinational, multicentre, non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorr...
    Medical condition: Postpartum haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004868 10005128 Bleeding postpartum LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000955-25 Sponsor Protocol Number: ClinDiab-08 Start Date*: 2017-05-12
    Sponsor Name:Medical University of Graz
    Full Title: A single-centre, open-label, randomized controlled trial of efficacy, safety and usability of a basal insulin algorithm incorporated in the GlucoTab system compared to standard care for glycaemic m...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004892-41 Sponsor Protocol Number: VT-001-0050 Start Date*: 2021-07-13
    Sponsor Name:Vera Therapeutics, Inc.
    Full Title: A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004628-23 Sponsor Protocol Number: M000507_6004 Start Date*: 2015-03-17
    Sponsor Name:Sanofi
    Full Title: Comparison of Teicoplanin and Vancomycin in Terms of Efficacy and Side Effect Profile During Initial Antibiotic Treatment of Febrile Neutropenic Patients at High Risk For Gram-Positive Infection: M...
    Medical condition: Neutropenic and febrile patients with hematological or solid tumors, who are at high risk for gram-positive bacterial infection.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10060945 Bacterial infection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003736-23 Sponsor Protocol Number: RR11/9229 Start Date*: 2012-11-26
    Sponsor Name:University of Leeds
    Full Title: RETREAT(F) (REmoval of Treatment for patients in REmission in psoriatic ArThritis – Feasibility study). A randomised controlled trial to compare withdrawal of therapy versus continuing therapy in l...
    Medical condition: psoriatic arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002322-37 Sponsor Protocol Number: 69HCL16_0123 Start Date*: 2016-12-07
    Sponsor Name:Hospices Civils de Lyon
    Full Title: TROPHIMMUN, a phase II trial of avelumab in chemo-resistant gestational trophoblastic neoplasias (GTN)
    Medical condition: Gestational trophoblastic neoplasias
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061988 Gestational trophoblastic tumour PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004961-42 Sponsor Protocol Number: BC-6226 Start Date*: 2020-08-06
    Sponsor Name:Ghent University Hospital
    Full Title: SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic profiling
    Medical condition: peripheral spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10051265 Spondyloarthropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2020-003605-55 Sponsor Protocol Number: 74556 Start Date*: 2021-01-15
    Sponsor Name:Erasmus MC - University Medical Centre
    Full Title: Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with oligometastatic disease
    Medical condition: Patients (18 – 75 years) who are diagnosed with adenocarcinoma of the oesophagus or GOJ with a resectable primary tumour and de-novo synchronous oligometastatic disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000301-71 Sponsor Protocol Number: TJB1117P1 Start Date*: 2013-01-25
    Sponsor Name:CHU-ULg
    Full Title: Donor Regulatory T cells (Treg) infusion (DTI) in patients with steroid-refractory chronic graft-versus-host disease (GVHD).
    Medical condition: Steroid-refractory chronic graft-versus-host-disease.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001097-18 Sponsor Protocol Number: CA209-331 Start Date*: 2015-09-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy
    Medical condition: Relapsed Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041070 Small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) HU (Completed) GR (Completed) PL (Completed) ES (Completed) FR (Completed) RO (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003761-16 Sponsor Protocol Number: 9818P Start Date*: 2005-11-24
    Sponsor Name:Department of R & D, Central Manchester and Manchester Children's Hospital NHS Trust
    Full Title: Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia
    Medical condition: Pneumococcal disease is a common form of meningitis, septicaemia and pneumonia. Those individuals at highest risk include children, the elderly and persons whose immune systems are impaired. This l...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003873-41 Sponsor Protocol Number: 14-23-16/07 Start Date*: 2015-07-09
    Sponsor Name:MAASTRO Clinic
    Full Title: Non invasive imaging of tumor hypoxia with [18F]HX4 Positron-Emission-Tomography (PET): A phase II trial
    Medical condition: Eligible patients with histologically/cytologically proven primary tumors of the prostate, esophagus, brain or rectum or metastatic disease to the brain (originating from breast, lung or colorectal...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003213-34 Sponsor Protocol Number: CH2012-001 Start Date*: 2012-11-13
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: MEthylprednisoloneNacinHepatIcResections “MENHIR”
    Medical condition: patients candidate to liver resection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004592-35 Sponsor Protocol Number: 6836 Start Date*: 2010-06-16
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Randomised Stratified Multicentre Phase II Clinical Trial of Single-Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients with Malignant Pleural Mesothelioma.
    Medical condition: Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 85  86  87  88  89  90  91  92  93  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 07:27:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA